Nicolás Ignacio Lara Salas

Mr. Nicolás Ignacio Lara Salas

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2026 in Life
Verified
Journal Article
Open access
PDF file
LALorena Carlota Albarracin
Lorena Carlota Albarracin
NSNicolás Ignacio Lara Salas
Nicolás Ignacio Lara Salas
JAJavier H. Alarcon-Roa
Javier H. Alarcon-Roa
MAMAYLIN ALMONTE ALMONTE-BECERRIL
MAYLIN ALMONTE ALMONTE-BECERRIL
EGEnmanuel Guerrero
Enmanuel Guerrero
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
Non-coding RNAs (ncRNAs) have emerged as promising biomarkers for prostate cancer (PCa), yet evidence remains dispersed across heterogeneous studies and their regulatory context is seldom analyzed in an integrated manner. This study systematically maps ncRNAs reported as diagnostic biomarkers for PCa and characterizes their molecular interactions through in silico analyses. A comprehensive evidence-mapping strategy across major bibliographic databases identified 693 studies, of which 58 met eligibility criteria. Differentially expressed ncRNAs were extracted and classified by RNA type. Subsequently, miRNA–target prediction, miRNA–protein interaction network construction, and functional enrichment analyses were performed to explore the regulatory landscape of miRNA-associated proteins. Results: The final dataset included 4500 participants (2871 PCa cases and 2093 controls) and reported 94 differentially expressed miRNAs, eight lncRNAs, and several circRNAs, snoRNAs, snRNAs, and piRNAs. In silico analyses predicted 13,493 miRNA–mRNA interactions converging on 4916 unique target genes, with an additional 2481 prostate tissue-specific targets. The miRNA–protein network comprised 845 nodes and 2335 edges, revealing highly connected miRNAs (e.g., hsa-miR-16-5p, hsa-miR-20a-5p) and protein hubs (QKI, YOD1, TBL1XR1; prostate-specific CDK6, ACVR2B). Enrichment analysis showed strong overrepresentation of metabolic process-related GO terms and cancer-associated KEGG pathways. Conclusions: These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.

30 September 2025 in Revista de la Facultad de Ciencias Médicas (Quito)
Verified
Journal Article
Open access
PDF file
JRJosue Rivadeneira
Josue Rivadeneira
LFLuis Ernesto Fuenmayor-González
Luis Ernesto Fuenmayor-González
NFNancy Flores-Lastra
Nancy Flores-Lastra
PHPablo Herrera-Jumbo
Pablo Herrera-Jumbo
MJMichelle Jácome-García
Michelle Jácome-García
NSNicolás Ignacio Lara Salas
Nicolás Ignacio Lara Salas
Introduction: Non-communicable diseases such as type 2 diabetes mellitus and dyslipidemias are highly prevalent in Ecuador. The Finnish Diabetes Risk Score (FINDRISC) measures the 10-year risk of developing diabetes, but its relationship with lipid profile has not been studied locally. This study examined the relationship between FINDRISC test results and total, HDL, and LDL cholesterol levels in Ecuadorian primary care patients. Objective: Analyze the relationship between the FINDRISC test score and lipid profile parameters in patients treated at primary care centers in Ecuador. Methods: A cross-sectional study was carried out in 236 adults without diabetes. The FINDRISC test score was calculated, and clinical and biochemical data were collected. Nonparametric tests were used to analyze correlations and differences between risk groups. Results: A moderate or higher risk of diabetes was present in 37.3% of participants. There were significant positive correlations between the FINDRISC score and both LDL (rho=0.37; p<0.001) and total cholesterol (rho=0.16; p=0.01). Intergroup differences were noted (p=0.04), but there was no correlation with HDL. Discussion: A higher FINDRISC score is associated with increased levels of total cholesterol and LDL, suggesting the tool may be useful for identifying broader metabolic risks beyond diabetes alone. While these findings align with existing research, the study's cross-sectional design and non-probabilistic sampling limit the ability to establish causality and generalize the results to the wider population. Conclusion: Higher LDL and total cholesterol levels are linked to increased FINDRISC scores. These findings support using the FINDRISC tool in primary care to identify broader metabolic risk

5 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
LALorena Carlota Albarracin
Lorena Carlota Albarracin
NSNicolás Ignacio Lara Salas
Nicolás Ignacio Lara Salas
JRJavier Alarcón Roa
Javier Alarcón Roa
MAMAYLIN ALMONTE ALMONTE-BECERRIL
MAYLIN ALMONTE ALMONTE-BECERRIL
EGEnmanuel Guerrero
Enmanuel Guerrero
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
Background: Non-coding RNAs (ncRNAs) have emerged as promising biomarkers for prostate cancer (PCa), yet evidence remains dispersed across heterogeneous studies and their regulatory context is seldom analyzed in an integrated manner. This study systematically maps ncRNAs reported as diagnostic biomarkers for PCa and characterizes their molecular interactions through in silico analyses. Methods: A comprehensive evidence-mapping strategy across major bibliographic databases identified 693 studies, of which 58 met eligibility criteria. Differentially expressed ncRNAs were extracted and classified by RNA type. Subsequently, miRNA–target prediction, miRNA–protein interaction network construction, and functional enrichment analyses were performed to explore the regulatory landscape of miRNA-associated proteins. Results: The final dataset included 4,500 participants (2,871 PCa cases and 2,093 controls) and reported 94 differentially expressed miRNAs, eight lncRNAs, and several circRNAs, snoRNAs, snRNAs, and piRNAs. In silico analyses predicted 13,493 miRNA–mRNA interactions converging on 4,916 unique target genes, with an additional 2,481 prostate tissue–specific targets. The miRNA–protein network comprised 845 nodes and 2,335 edges, revealing highly connected miRNAs (e.g., hsa-miR-16-5p, hsa-miR-20a-5p) and protein hubs (QKI, YOD1, TBL1XR1; prostate-specific CDK6, ACVR2B). Enrichment analysis showed strong overrepresentation of metabolic process–related GO terms and cancer-associated KEGG pathways. Conclusions: These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.